An Infectious Run

Written by GSCR Staff   
Wednesday, 13 March 2013 10:41

Good morning!  We have another rolling biotech stock for today.

Trius Therapeutics. Inc. (NASAQ – TSRX - $6.21) is on the verge of a major breakthrough that could prove to be very profitable for shareholders.  The biopharmaceutical Company’s primary focus is on the development and selling of antibiotics for life-threatening infections.

Trius Therapeutics’ flagship product, Tedizolid phosphate (TR-701), is an orally administrated second generation oxazolidnone that is used for the treatment of serious bacterial skin and skin structure infections, and serious gram-positive infections, including MRSA (methicillin-resistant Staphylococcus aureus). These MRSA have received a lot of notoriety recently as they part of the multi-drug-resistant organisms (MDROs) family.  MSRA infections have doubled in the last five years even by conservative estimates.  TR-701 has completed Phase III clinical development and expected to complete its second Phase III trial by the end of 1Q13.

Additionally, the Company has a license agreement with Dong-A Pharmaceutical Co., Ltd. to develop and commercialize licensed products, including tedizolid phosphate, outside of Korea; a cooperative research and development agreement with Lawrence Livermore National Security LLC for researching and developing gram-negative biodefense pathogens; a research agreement with UCSD for jointly researching antibacterial agents for combating gram-negative and gram-positive biodefense pathogens; a research contract with Lawrence Livermore National Laboratory for the development of antibiotics directed against gram negative multi-drug resistant bacterial pathogens; and a collaboration and license agreement with Bayer to develop and commercialize tedizolid phosphate in the Bayer licensed territory. 

TSRX has been on a run from $4.86 at the start of the year to current levels of over $6.00, via heavy volumes.  That tells us there is some major accumulation going on here.  The charts are very bullish and there could be a break out once the stock hits $6.50, coincidentally, one penny higher than the 52-week high.  We think that happens easily and think the stock gets to $9.00 in 2Q13.

Have a great day! 

Disclosure: Goldman Small Cap Research analysts are neither long nor short these shares but may elect to purchase the stock within the next 48 hours. 

Disclaimer:

This Market Monitor blog was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research, which typically highlights small cap companies, and Goldman Opportunity Research, which features micro cap companies in a sponsored research format. Thus, the Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports.

It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.

ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS   INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com  

 

Add comment
  • No comments found